Albis Hani

Albis Hani

Auto-generated profile, based on publicly available information

Albis Hani

Pontificia Universidad Javeriana

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ASAmi D. Sperber
Ami D. Sperber
SBShrikant I. Bangdiwala
Shrikant I. Bangdiwala
DDDouglas A. Drossman
Douglas A. Drossman
UGUday C. Ghoshal
Uday C. Ghoshal
MSMagnus Simren
Magnus Simren
OPOlafur S. Palsson
Olafur S. Palsson
Background & Aims Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. Methods Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs. Data collection methods differed for Internet and household groups, so data analyses were conducted and reported separately. Results Among the 73,076 adult respondents (49.5% women), diagnostic criteria were met for at least 1 FGID by 40.3% persons who completed the Internet surveys (95% confidence interval [CI], 39.9–40.7) and 20.7% of persons who completed the household surveys (95% CI, 20.2–21.3). FGIDs were more prevalent among women than men, based on responses to the Internet survey (odds ratio, 1.7; 95% CI, 1.6–1.7) and household survey (odds ratio, 1.3; 95% CI, 1.3–1.4). FGIDs were associated with lower quality of life and more frequent doctor visits. Proportions of subjects with irritable bowel syndrome were lower when the Rome IV criteria were used, compared with the Rome III criteria, in the Internet survey (4.1% vs 10.1%) and household survey (1.5% vs 3.5%). Conclusions In a large-scale multinational study, we found that more than 40% of persons worldwide have FGIDs, which affect quality of life and health care use. Although the absolute prevalence was higher among Internet respondents, similar trends and relative distributions were found in people who completed Internet vs personal interviews.

29 January 2017 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
IMI. Marin
I. Marin
DCD. Cisternas
D. Cisternas
LAL. Abrao
L. Abrao
ELE. Lemme
E. Lemme
CBC. Bilder
C. Bilder
JSJ. Serra
J. Serra

1 June 2013 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MPMark Pimentel
Mark Pimentel
NTNicholas J. Talley
Nicholas J. Talley
EQEamonn M.M. Quigley
Eamonn M.M. Quigley
AHAlbis Hani
Albis Hani
ASAla Sharara
Ala Sharara
VMVarocha Mahachai
Varocha Mahachai
In 2012, a group of 29 internationally recognized experts in the pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the current state of IBS research. The meeting was preceded by a comprehensive online survey that focused on research needs for IBS diagnosis (particularly the strengths and shortcomings of current criteria), definitions used in clinical trials for IBS patients and “healthy controls,” potential biomarkers for IBS, and outcome measures in drug trials. While the purpose of the meeting was not to make binding recommendations, participants developed a framework for future questions and research needs in IBS. First, participants indicated the need for revised criteria for the diagnosis of IBS; in particular, inclusion of bloating and de-emphasis of pain as criteria were considered critical needs. Second, participants noted that definitions of normal, healthy controls varied widely among clinical trials; these definitions need to be standardized not only to improve the reliability of results, but also to better facilitate inter-trial comparisons and data synthesis. Third, participants highlighted the need for accurate biomarkers of disease. Fourth and finally, participants noted that further defining outcome measures, so that they are functionally relevant and reflect normalization of bowel function, is a critical need. Together, the discussions held at this workshop form a framework to address future research in IBS.

8 July 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
WKW. F. W. Kappelle
W. F. W. Kappelle
ABA. J. Bredenoord
A. J. Bredenoord
JCJ. M. Conchillo
J. M. Conchillo
JRJ. P. Ruurda
J. P. Ruurda
NBN. D. Bouvy
N. D. Bouvy
PSP. D. Siersema
P. D. Siersema
Summary: Background: A previous single‐centre study showed that lower oesophageal sphincter electrical stimulation therapy (LES‐EST) in gastro‐oesophageal reflux disease (GERD) patients improves reflux symptoms and decreases oesophageal acid exposure.Aim: To evaluate safety and efficacy of LES‐EST in GERD patients with incomplete response to proton pump inhibitors (PPIs) in a prospective, international, multicentre, open‐label study.Methods: GERD patients, partially responsive to PPIs, received LES‐EST. GERD health‐related quality of life (GERD‐HRQL), daily symptom diaries, quality of life scores, oesophageal acid exposure, and LES resting and residual pressure were measured before and after initiation of LES‐EST. Stimulation sessions were optimised based on residual symptoms and oesophageal acid exposure.Results: Forty‐four patients were enrolled and 6‐month data from 41 patients are available. Hiatal repair was performed in 16 patients. One device‐related, one procedure‐related and one unrelated severe adverse event were reported. GERD‐HRQL improved from 31.0 (IQR 26.2–36.8) off‐PPI and 16.5 (IQR 9.0–22.8) on‐PPI to 4 (IQR 1–8) at 3‐month and 5 (IQR 3–9) at 6‐month follow‐up (P < 0.0001 vs. on‐ and off‐PPI). Oesophageal acid exposure (pH < 4.0) improved from 10.0% (IQR 7.5–12.9) to 3.8% (IQR 1.9–12.3) at 3 months (P = 0.0027) and 4.4% (IQR 2.2–7.2) at 6 months (P < 0.0001).Conclusions: These interim results show an acceptable safety record of LES‐EST to date, combined with good short‐term efficacy in GERD patients who are partially responsive to PPI therapy. A remarkable reduction in regurgitation symptoms, without the risk of intervention‐requiring dysphagia may prove to be an advantage compared with other anti‐reflux procedures. ClinicalTrials.gov Identifier: NCT01574339.

29 March 2023 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
MSMax J. Schmulson
Max J. Schmulson
GPGerardo A. Puentes‐Leal
Gerardo A. Puentes‐Leal
LBLuis Bustos‐Fernández
Luis Bustos‐Fernández
CFCarlos Francisconi
Carlos Francisconi
AHAlbis Hani
Albis Hani
ASAmi D. Sperber
Ami D. Sperber
Background: In Latin America, there are scarce data on the epidemiology of DGBI. The Rome Foundation Global Epidemiology Study (RFGES) Internet survey included 26 countries, four from Latin America: Argentina, Brazil, Colombia, and Mexico, with a 40.3% prevalence of Rome IV DGBI. We aimed at comparing the prevalence of DGBI and associated factors among these countries.Methods: The frequency of DGBI by anatomical region, specific diagnoses, sex, age, diet, healthcare access, anxiety, depression, and HRQOL, were analyzed and compared.Results: Subjects included Argentina n = 2057, Brazil = 2004, Colombia = 2007, and Mexico = 2001. The most common DGBI were bowel (35.5%), gastroduodenal (11.9%), and anorectal (10.0%). Argentina had the highest prevalence of functional diarrhea (p = 0.006) and IBS‐D; Brazil, esophageal, gastroduodenal disorders, and functional dyspepsia; Mexico functional heartburn (all <0.001). Overall, DGBI were more common in women vs. men and decreased with age. Bowel disorders were more common in the 18–39 (46%) vs. 40–64‐year (39%) groups. Diet was also different between those with DGBI vs. those without with subtle differences between countries. Subjects endorsing criteria for esophageal, gastroduodenal, and anorectal disorders from Mexico, more commonly consulted physicians for bowel symptoms vs. those from Argentina, Brazil, and Colombia. General practitioners were the most frequently consulted, by Mexicans (50.42%) and Colombians (40.80%), followed by gastroenterologists. Anxiety and depression were more common in DGBI individuals in Argentina and Brazil vs. Mexico and Colombia, and they had lower HRQOL.Conclusions: The prevalence of upper and lower DGBI, as well as the burden of illness, psychological impact and HRQOL, differ between these Latin American countries.

1 April 2017 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
HMH Monrroy
H Monrroy
DCD Cisternas
D Cisternas
CBC Bilder
C Bilder
ADA Ditaranto
A Ditaranto
JRJ Remes-Troche
J Remes-Troche
MVM A Valdovinos
M A Valdovinos
High-resolution manometry (HRM) is the preferred method for the evaluation of motility disorders. Recently, an update of the diagnostic criteria (Chicago 3.0) has been published. The aim of this study was to compare the performance criteria of Chicago version 2.0 (CC2.0) vs. 3.0 (CC3.0) in a cohort of healthy volunteers and symptomatic patients. HRM studies of asymptomatic and symptomatic individuals from several centers of Spain and Latin America were analyzed using both CC2.0 and CC3.0. The final diagnosis was grouped into hierarchical categories: obstruction (achalasia and gastro-esophageal junction obstruction), major disorders (distal esophageal spasm, absent peristalsis, and jackhammer), minor disorders (failed frequent peristalsis, weak peristalsis with small or large defects, ineffective esophageal motility, fragmented peristalsis, rapid contractile with normal latency and hypertensive peristalsis) and normal. The results were compared using McNemar's and Kappa tests. HRM was analyzed in 107 healthy volunteers (53.3% female; 18-69 years) and 400 symptomatic patients (58.5% female; 18-90 years). In healthy volunteers, using CC2.0 and CC3.0, obstructive disorders were diagnosed in 7.5% and 5.6%, respectively, major disorders in 1% and 2.8%, respectively, minor disorders in 25.2% and 15%, respectively, and normal in 66.4% and 76.6%, respectively. In symptomatic individuals, using CC2.0 and CC3.0, obstructive disorders were diagnosed in 11% and 11.3%, respectively, major disorders in 14% and 14%, respectively, minor disorders in 33.3% and 24.5%, respectively, and normal in 41.8% and 50.3%, respectively. In both groups of individuals, only an increase in normal and a decrease in minor findings using CC3.0 were statistically significant using McNemar's test. CC3.0 increases the number of normal studies when compared with CC2.0, essentially at the expense of fewer minor disorders, with no significant differences in major or obstructive disorders. As the relevance of minor disorders is questionable, our data suggest that CC3.0 increases the relevance of abnormal results.